Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Zymeworks targets August 25, 2026 PDUFA date for zanidatamab approval, potentially unlocking $250M U.S. milestone and up to $190M in global regulatory milestones.
Relay Therapeutics selected zovegalisib plus atirmociclib as the go-forward triplet regimen for first-line (1L) breast cancer, with a Phase 3 trial expected to initiate in early 2027.
